Diabetes Care, Vol 16, Issue 4 584-592, Copyright © 1993 by American Diabetes Association

ARTICLES

Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes

S Lahdenpera, M Tilly-Kiesi, H Vuorinen-Markkola, T Kuusi and MR Taskinen
Second Department of Medicine, University of Helsinki, Finland.

OBJECTIVE--To study the effects of gemfibrozil treatment on LDL particle size, density distribution, and composition in NIDDM patients. RESEARCH DESIGN AND METHODS--We performed LDL analyses on 16 NIDDM patients with stable glycemic control. They were randomly allocated to receive either gemfibrozil (n = 8) or a placebo (n = 8) for 3 mo in a double-blind study. The LDL particle size distribution and the particle diameter of the major LDL peak were measured with nondenaturing polyacrylamide gradient gel electrophoresis. The density distribution and composition of LDL were determined with the density gradient ultracentrifugation method. RESULTS--In the gemfibrozil group the mean serum TG concentration decreased by 38%, HDL cholesterol concentration increased by 10%, and LDL cholesterol concentration by 17% (P < 0.05). During gemfibrozil therapy the mean particle diameter of the major LDL peak increased from 244 to 251 A (P < 0.05), whereas in the placebo group the mean LDL particle diameter remained unchanged. We found an inverse correlation between the changes of serum TG and the particle diameters of the major LDL peak (r = 0.85, P < 0.01). Gemfibrozil produced a shift in the LDL density distribution toward lower density. The mean peak density decreased from 1.0371 to 1.0345 g/ml because of a significant rise in the light LDL concentration from 141.0 to 183.2 mg/dl (P < 0.05), whereas the concentration of dense LDL had a tendency to decrease. In the placebo group the LDL density distribution did not change. Gemfibrozil increased the CE-to-TG ratio in LDL core lipids by 27% (P < 0.05); otherwise, the LDL composition was only slightly affected. CONCLUSIONS--The results indicate gemfibrozil-induced changes in LDL properties in NIDDM patients are similar to those previously reported in nondiabetic individuals and are related to changes in serum TG level.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. S. Birjmohun, B. A. Hutten, J. J.P. Kastelein, and E. S.G. Stroes Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials J. Am. Coll. Cardiol., January 18, 2005; 45(2): 185 - 197. [Abstract] [Full Text] [PDF]

				T. Kaitosaari, T. Ronnemaa, O. Raitakari, S. Talvia, K. Kallio, I. Volanen, A. Leino, E. Jokinen, I. Valimaki, J. Viikari, et al. Effect of 7-Year Infancy-Onset Dietary Intervention on Serum Lipoproteins and Lipoprotein Subclasses in Healthy Children in the Prospective, Randomized Special Turku Coronary Risk Factor Intervention Project for Children (STRIP) Study Circulation, August 12, 2003; 108(6): 672 - 677. [Abstract] [Full Text] [PDF]

				A. M. Wagner, O. Jorba, R. Bonet, J. Ordonez-Llanos, and A. Perez Efficacy of Atorvastatin and Gemfibrozil, Alone and in Low Dose Combination, in the Treatment of Diabetic Dyslipidemia J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3212 - 3217. [Abstract] [Full Text] [PDF]

				M. Petersen, H. Pedersen, A. Major-Pedersen, T. Jensen, and P. Marckmann Effect of Fish Oil Versus Corn Oil Supplementation on LDL and HDL Subclasses in Type 2 Diabetic Patients Diabetes Care, October 1, 2002; 25(10): 1704 - 1708. [Abstract] [Full Text] [PDF]

				J. Jeppesen, H. O. Hein, P. Suadicani, and F. Gyntelberg Low Triglycerides-High High-Density Lipoprotein Cholesterol and Risk of Ischemic Heart Disease Arch Intern Med, February 12, 2001; 161(3): 361 - 366. [Abstract] [Full Text] [PDF]

				A. WAKATSUKI, N. IKENOUE, Y. OKATANI, and C. IZUMIYA Lipid Transfer Reactions and Lipid Composition of Low-Density Lipoprotein Particles in Postmenopausal Women Receiving Estrogen Obstet. Gynecol., October 1, 1999; 94(4): 492 - 497. [Abstract] [Full Text] [PDF]

				B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.-C. Fruchart Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism Circulation, November 10, 1998; 98(19): 2088 - 2093. [Abstract] [Full Text] [PDF]

				J o. Jeppesen, H. O. Hein, P. Suadicani, and F. Gyntelberg Triglyceride Concentration and Ischemic Heart Disease : An Eight-Year Follow-up in the Copenhagen Male Study Circulation, March 24, 1998; 97(11): 1029 - 1036. [Abstract] [Full Text] [PDF]

				M. Ayaori, T. Ishikawa, H. Yoshida, M. Suzukawa, M. Nishiwaki, H. Shige, T. Ito, K. Nakajima, K. Higashi, A. Yonemura, et al. Beneficial Effects of Alcohol Withdrawal on LDL Particle Size Distribution and Oxidative Susceptibility in Subjects With Alcohol-Induced Hypertriglyceridemia Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2540 - 2547. [Abstract] [Full Text]

				C. M. Beard, R. J. Barnard, D. C. Robbins, J. M. Ordovas, and E. J. Schaefer Effects of Diet and Exercise on Qualitative and Quantitative Measures of LDL and Its Susceptibility to Oxidation Arterioscler. Thromb. Vasc. Biol., February 1, 1996; 16(2): 201 - 207. [Abstract] [Full Text]

				M. A. Austin, L. Mykkanen, J. Kuusisto, K. L. Edwards, C. Nelson, S. M. Haffner, K. Pyorala, and M. Laakso Prospective Study of Small LDLs as a Risk Factor for Non–Insulin Dependent Diabetes Mellitus in Elderly Men and Women Circulation, October 1, 1995; 92(7): 1770 - 1778. [Abstract] [Full Text]